Integrated pan-cancer profiling and experimental validation identify CCDC59 as a key driver and therapeutic biomarker in liver hepatocellular carcinoma - PubMed
8 hours ago
- #Pan-Cancer Analysis
- #Liver Cancer
- #Biomarker
- CCDC59 is overexpressed in multiple cancers, particularly in bladder cancer.
- High CCDC59 expression correlates with poor prognosis in cancers like LIHC and KIRP.
- CCDC59 is linked to immune infiltration, DNA damage pathways, and cell cycle regulation.
- Knockdown of CCDC59 in LIHC cells reduces proliferation, migration, and invasion.
- Targeting CCDC59 may enhance immunotherapy and chemotherapy efficacy in LIHC.